Literature DB >> 29141919

Rare Tumors in Kids May Respond to Tazemetostat.

.   

Abstract

In a phase I trial of the EZH2 inhibitor tazemetostat, children with INI1-deficient tumors-including relapsed or refractory malignant rhabdoid tumors, atypical teratoid rhabdoid tumors, epithelioid sarcomas, and poorly differentiated chordomas-responded well to treatment, with some experiencing durable responses. ©2017 American Association for Cancer Research.

Entities:  

Year:  2017        PMID： 29141919     DOI： 10.1158/2159-8290.CD-NB2017-152

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  1 in total

1.  Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models.

Authors:  Charlotte Gatzweiler; Johannes Ridinger; Sonja Herter; Xenia F Gerloff; Dina ElHarouni; Yannick Berker; Roland Imle; Lukas Schmitt; Sina Kreth; Sabine Stainczyk; Simay Ayhan; Sara Najafi; Damir Krunic; Karen Frese; Benjamin Meder; David Reuss; Petra Fiesel; Kathrin Schramm; Mirjam Blattner-Johnson; David T W Jones; Ana Banito; Frank Westermann; Sina Oppermann; Till Milde; Heike Peterziel; Olaf Witt; Ina Oehme
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.